Alli Sales Slender On Lower Retailer Demand, Flatten GSK Consumer Sales

By Jessica Lake / Email the Author / “The Tan Sheet” Jul. 28, 2008, Vol. 16, No. 030
Sales & Earnings / Word Count: 605 / Article # 05160300003

Executive Summary

Significantly lower sales of GlaxoSmithKline's alli OTC weight-loss drug combined with struggles in the nicotine replacement therapy category weighed down the consumer health care division's performance in the firm's latest quarter

Purchase this Article

$35.00 Buy Now

For $35.00, purchase this 605-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Alli Sales Slender On Lower Retailer Demand, Flatten GSK Consumer Sales

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to “The Tan Sheet” will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

Alli Sales Slender On Lower Retailer Demand, Flatten GSK Consumer Sales

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 8

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article